TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00370149

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic-impregnated Catheters (M/R)
Description: Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-impregnated Catheters (C/S)
Description: Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
Study: NCT00787332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desirudin or Argatroban®
Description: Desirudin 15mg SC Argatroban® IV dosing per Package Insert
Study: NCT02621567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy Lamp
Description: TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps emit light of intensity 10,000 lux.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Modified Dim Lamp
Description: TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps have been modified to emit light of intensity 500 lux.
Study: NCT02891590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTRMWXHS-12
Study: NCT03801720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Using ultrasound stimulation to induce micturition.
Study: NCT02809027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginger

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Study: NCT04103047

Intervention type: OTHER
Intervention: SAD
Description: The patients who have an SAD inserted as part of their normal Anaesthetic plan will be consented prior to their Anaesthetic and then have a questionnaire to fill out post operatively.
Study: NCT04307602

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise - High Intensity Interval Training (HIIT)
Description: Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled children

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - High Intensity Interval Training (HIIT)
Description: Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled children

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise - High Intensity Interval Training (HIIT)
Description: Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled children

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise - Submaximal Steady State Training (SST)
Description: Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - Submaximal Steady State Training (SST)
Description: Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise - Submaximal Steady State Training (SST)
Description: Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled
Study: NCT01290016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 servings dairy + exercise
Description: Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 servings dairy + exercise
Description: Subjects in this group will receive family based counseling to increase intake of dairy to 4 servings per day and also receive instruction on how to improve their physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 servings dairy + exercise
Description: Subjects in this group will receive family based counseling to increase intake of dairy to 4 servings per day and also receive instruction on how to improve their physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
Study: NCT04443920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid (TXA)
Description: Randomly assigned \[1:1 ratio\] using a computer generated table of random numbers to 1 of the 2 intervention groups
Study: NCT02140476

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar vessel sealing and cutting device
Description: This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar vessel sealing and cutting device
Description: This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional thyroidectomy
Description: Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional thyroidectomy
Description: Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
Study: NCT01277042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK580299 (CervarixTM)
Description: 3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-BTM
Description: 3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
Study: NCT04443920

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Normal Saline (NS)
Description: Randomly assigned \[1:1 ratio\] using a computer generated table of random numbers to 1 of the 2 intervention groups
Study: NCT01617083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Antibiotic used to treat infections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Thickening compound with sugar and flavoring
Study: NCT03503838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Yoga
Description: 12 weeks of online yoga; 60 min/week
Study: NCT03149315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420mg, PO once daily for 2-7 days
Study: NCT03306186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemoSpec
Description: Blood sampling for analysis
Study: NCT02662595

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS reminder message

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voice call + SMS message
Study: NCT00948259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP031112
Description: unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
Study: NCT00635843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAVERICK™ Disc
Description: The MAVERICK™ disc is a spinal arthroplasty system and is intended to replace a damaged disc in the lumbar spine. It is a permanent implant used to maintain motion at the treated level and is inserted using an anterior surgical approach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft
Description: The control is the treatment with LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft. It is commercially available for anterior lumbar spine interbody fusion procedures.
Study: NCT03479060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wet Cupping
Description: cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Bloodletting and secondary suction and Removing and dressing
Study: NCT00688506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combined sono-electro-magnetic therapy (Sonodyn Medico Star)
Description: twice a day for 10 minutes during 12 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo therapy (Placebo Sonodyn Medico Star)
Description: twice a day for 10 minutes during 12 weeks
Study: NCT03696979

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial induction therapy
Description: Myofascial induction therapy is a therapy concept focused on optimizing function and balance within the fascial system. The approach aims at global recovery, local correction and painless body use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic pain education
Description: Therapeutic pain education is a training intervention that aims to reduce pain and disability by helping patients better understand the biological processes that support pain states. The neurobiology of pain and pain processed by the nervous system is explained to the patient in detail. Changes the patient's olab viewpoint to pain. For example, the patient believes that the cause of pain is caused by tissue damage. The patient who receives pain training understands that the cause of pain is the hypersensitive central nervous system. As a result, the patient's fear avoidance behavior decreases and he starts to move more easily. Because the sensitivity of the central nervous system will be alleviated, the perceived pain will decrease.
Study: NCT01212263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Step-up HP u FSH
Description: HP u FSH (Fostimone 75 IU ,IBSA Institut Biochimique SA-CH 6903 Lugano) in doses of 37.5 IU (half ampole) im /day statrted from second day of the cycle for 7 days ,then increased to 75 IU for another 7 days ,then to 112.5 IU (one and half ampoule) untilleading follicle mean diameter reaches 18 mm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphine citrate plus low dose uFSH
Description: Clomiphene citrate 50 mg tab oral tablets(Clomid 50 mg tablets Global Napi , Egypt) two tablets(100 mg) /day are started from the 2nd day of cycle for 5 days togeteher with 37.5 IU HP uFSH (Fostimone 75 IU IBSA)/day for 8 days and may be extended to 10-12 days until leading follicle diameter reaches 18 mm
Study: NCT00615602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6 mg/Kg IV over 30 min every two weeks for 4 cycles. Subsequently,trastuzumab 6 mg/Kg IV over 30 min for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
Study: NCT00787332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desirudin or Argatroban®
Description: Desirudin 15mg SC Argatroban® IV dosing per Package Insert
Study: NCT00615602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoruracil
Description: 5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
Study: NCT04788719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Gait analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Gait analysis
Study: NCT00615602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoruracil
Description: 5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
Study: NCT02517047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CareTRx
Description: CareTRx is a novel device that can be applied to most MDI (meter dose inhaler) device and leverages mobile and cloud computing to objectively assess and provide real-visualize feedback to patients and providers around medication adherence and disease control in pediatric asthma.
Study: NCT04359446

Intervention type: PROCEDURE
Group type: OTHER
Intervention: NC ( Non- Compliant) Balloon dilatation
Description: NC Balloon dilatation at pressure \> NC-RBP (18-20 atm) with \> 1 long inflation (\> 20 minutes each)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser Excimer + NC Balloon
Description: Laser Excimer + NC Balloon dilatation at pressure \> NC-RBP (18-20 atm) with \> 1 long inflation (\> 20 minutes each)
Study: NCT00615602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating growth factor
Description: rhG-CSF 5 μg/kg/d on days 3-10 after each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating growth factor
Description: rhG-CSF 5 μg/kg/d on days 3-10 after each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6mg/Kg IV over 30 min every 2 weeks for 4 cycles. Subsequently, trastuzumab 6mg/Kg IV over 30 min for 6 months
Study: NCT04974502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment
Description: Oral hygiene instructions, scaling and root planning.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment
Description: Oral hygiene instructions, scaling and root planning.
Study: NCT04117061

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Patient after primary investigation is observed for 8-12 hours, (instead of being send directly to CT scan), after observation repeated clinical evaluation, laboratory tests and ultrasound examination are done , if final diagnosis stays unclear the patient is refered to CT scan.
Study: NCT03826212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soybean Germ Extract
Description: Soybean Germ Extract 1,600 mg/day for 12 weeks.
Study: NCT00690937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric coated sevelamer
Description: Drug treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric coated sevelamer
Description: Drug treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam Cholestagel
Description: Drug comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02549677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: epirubicin, 90mg per square meter, every 3 weeks, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel, 75mg per square meter, every 3 weeks, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide, 600mg per square meter, every 3 weeks, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
Study: NCT00828867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg GSK investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg GSK investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg GSK investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg GSK investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2000 mg GSK investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1500 mg GSK investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg fed GSK investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3000mg GSK investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4000mg GSK investigational drug
Study: NCT04174131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane + Lidocaine
Description: Restylane + Lidocaine is a HA gel generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine. It is indicated for mid-to-deep dermal implantation for the correction of moderate to severe facial wrinkles and folds, such as NLFs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane + Lidocaine
Description: Restylane + Lidocaine is a HA gel generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine. It is indicated for mid-to-deep dermal implantation for the correction of moderate to severe facial wrinkles and folds, such as NLFs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Lyft
Description: Restylane® Lyft is a sterile gel of HA with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation (Galderma Laboratories, 2014).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Lyft
Description: Restylane® Lyft is a sterile gel of HA with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation (Galderma Laboratories, 2014).
Study: NCT04270851

Intervention type: DIAGNOSTIC_TEST
Intervention: LiMAx test
Description: The LiMAx test is a fully licenced liver function test, testing liver maximum capacity via a breath test.

Intervention type: DIAGNOSTIC_TEST
Intervention: HepaT1ca magnetic resonance scan
Description: The HepaT1ca scan is a pre-operative magnetic resonance scan providing a detailed report permitting interactive virtual pre-operative planning prior to liver surgery.
Study: NCT01682369

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TIV (Aggripal)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TIV (Aggripal)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TIV (Aggripal)
Study: NCT03826212

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1,600 mg/day for 12 weeks.
Study: NCT01682369

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ATIV (Fluad)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ATIV (Fluad)
Study: NCT03351361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab
Description: Nivolumab dosed intravenously over 30 minutes at 240 mg every 2 weeks combined with Ipilimumab dosed intravenously over 30 minutes at 1 mg/kg every 6 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Doublet of chemotherapy according to standard of care carboplatin (AUC 5) with a dose that will be capped to 700 mg and pemetrexed (500 mg/m²) over 4 to 6 hours every three weeks (restricted to non-squamous histology) or carboplatin (AUC 6) with a dose that will be capped to 700 mg and paclitaxel (90 mg/m²) D1 D8 D15 over 4 to 6 hours every 4 weeks, with a maximum of 4 cycles of carboplatin based doublet, and the possibility to use maintenance with pemetrexed.
Study: NCT02696720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT01244763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral capsule
Study: NCT01682369

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ATIV (Fluad)
Study: NCT00164905

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Doppler ultrasound probe
Description: Applying to ulcer base to assess the blood flow underneath the ulcer
Study: NCT00421863

Intervention type: DRUG
Group type: OTHER
Intervention: Catapresan TTS 2
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study: NCT00995735

Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Cholecystectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.

Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Cholecystectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Appendectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
Study: NCT00995735

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Appendectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.